Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

Daniel Morales; Anna Ostropolets; Lana  Lai; Anthony  Sena; Scott DuVall; Marc  Suchard; Katia  Verhamme; Peter Rjinbeek; Joe Posada; Waheed Ahmed; Thamer Alshammary; Heba Alghoul; Osaid Asler; Carlos Areia; Clair Blacketer; Ed Burn; Paula Casajust; Seng  You; Dalia Dawoud; Asieh Golozar; Menchung  Gong; Jitendra Jonnagaddala; Kristine  Lynch; Michael E. Matheny; Evan  Minty; Fredrik Nyberg; Albert Uribe; Martina Recalde; Christian Reich; Martijn Scheumie; Karishma Shah; Nigam  Shah; Lisa  Schilling; David Vizcaya; Lin Zhang; George Hripcsak; Patrick Ryan; Daniel Prieto-Alhambra; Duarte-Salles Talita; Kristin  Kostka

doi:10.1080/02770903.2021.2025392

Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

Daniel Morales (Lead / Corresponding author), Anna Ostropolets, Lana Lai, Anthony Sena, Scott DuVall, Marc Suchard, Katia Verhamme, Peter Rjinbeek, Joe Posada, Waheed Ahmed, Thamer Alshammary, Heba Alghoul, Osaid Asler, Carlos Areia, Clair Blacketer, Ed Burn, Paula Casajust, Seng You, Dalia Dawoud, Asieh GolozarMenchung Gong, Jitendra Jonnagaddala, Kristine Lynch, Michael E. Matheny, Evan Minty, Fredrik Nyberg, Albert Uribe, Martina Recalde, Christian Reich, Martijn Scheumie, Karishma Shah, Nigam Shah, Lisa Schilling, David Vizcaya, Lin Zhang, George Hripcsak, Patrick Ryan, Daniel Prieto-Alhambra, Duarte-Salles Talita, Kristin Kostka

Population Health and Genomics

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

73 Downloads (Pure)

Abstract

Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma.

Methods: We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients (‘diagnosed’ and ‘hospitalized’) based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions.

Results: The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6–8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7–6.8) to 18.5% (95% CI 18.2–18.8) in the diagnosed cohort and 5.2% (95% CI 4.0–6.8) to 20.5% (95% CI 18.6–22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8–2.4) to 16.9% (95% CI 13.8–20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15–30% of hospitalized COVID-19 asthma patients.

Conclusion: The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients. KEY MESSAGES Asthma prevalence in COVID-19 patients varied internationally (5.2–20.5%).The prevalence of asthma exacerbation at presentation with COVID-19 in diagnosed and hospitalized patients was low. Comorbidities were common in COVID-19 patients with asthma.

Original language	English
Pages (from-to)	76-86
Number of pages	11
Journal	Journal of Asthma
Volume	60
Issue number	1
Early online date	10 Jan 2022
DOIs	https://doi.org/10.1080/02770903.2021.2025392
Publication status	Published - 2023

Keywords

asthma
COVID-19
comorbidity
epidemiology
Asthma

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Pediatrics, Perinatology, and Child Health
Immunology and Allergy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/02770903.2021.2025392Licence: CC BY

Final published versionFinal published version, 1.53 MBLicence: CC BY

Cite this

Morales, D., Ostropolets, A., Lai, L., Sena, A., DuVall, S., Suchard, M., Verhamme, K., Rjinbeek, P., Posada, J., Ahmed, W., Alshammary, T., Alghoul, H., Asler, O., Areia, C., Blacketer, C., Burn, E., Casajust, P., You, S., Dawoud, D., ... Kostka, K. (2023). Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe. Journal of Asthma, 60(1), 76-86. https://doi.org/10.1080/02770903.2021.2025392

@article{9d4eee3448884921a1eefd2233fdb9bf,

title = "Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe",

abstract = "Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma.Methods: We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients ({\textquoteleft}diagnosed{\textquoteright} and {\textquoteleft}hospitalized{\textquoteright}) based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions.Results: The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6–8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7–6.8) to 18.5% (95% CI 18.2–18.8) in the diagnosed cohort and 5.2% (95% CI 4.0–6.8) to 20.5% (95% CI 18.6–22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8–2.4) to 16.9% (95% CI 13.8–20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15–30% of hospitalized COVID-19 asthma patients.Conclusion: The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients. KEY MESSAGES Asthma prevalence in COVID-19 patients varied internationally (5.2–20.5%).The prevalence of asthma exacerbation at presentation with COVID-19 in diagnosed and hospitalized patients was low. Comorbidities were common in COVID-19 patients with asthma.",

keywords = "asthma, COVID-19, comorbidity, epidemiology, Asthma",

author = "Daniel Morales and Anna Ostropolets and Lana Lai and Anthony Sena and Scott DuVall and Marc Suchard and Katia Verhamme and Peter Rjinbeek and Joe Posada and Waheed Ahmed and Thamer Alshammary and Heba Alghoul and Osaid Asler and Carlos Areia and Clair Blacketer and Ed Burn and Paula Casajust and Seng You and Dalia Dawoud and Asieh Golozar and Menchung Gong and Jitendra Jonnagaddala and Kristine Lynch and Matheny, {Michael E.} and Evan Minty and Fredrik Nyberg and Albert Uribe and Martina Recalde and Christian Reich and Martijn Scheumie and Karishma Shah and Nigam Shah and Lisa Schilling and David Vizcaya and Lin Zhang and George Hripcsak and Patrick Ryan and Daniel Prieto-Alhambra and Duarte-Salles Talita and Kristin Kostka",

note = "Funding Information: This study was supported by Wellcome Trust (Grant 214588/Z/18/Z), Bill & Melinda Gates Foundation (Investment ID INV-016201 and INV-019257), Innovative Medicines Initiative 2 Joint Undertaking (No 806968). Copyright: {\textcopyright} 2022 the author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2023",

doi = "10.1080/02770903.2021.2025392",

language = "English",

volume = "60",

pages = "76--86",

journal = "Journal of Asthma",

issn = "0277-0903",

publisher = "Informa Healthcare",

number = "1",

}

Morales, D, Ostropolets, A, Lai, L, Sena, A, DuVall, S, Suchard, M, Verhamme, K, Rjinbeek, P, Posada, J, Ahmed, W, Alshammary, T, Alghoul, H, Asler, O, Areia, C, Blacketer, C, Burn, E, Casajust, P, You, S, Dawoud, D, Golozar, A, Gong, M, Jonnagaddala, J, Lynch, K, Matheny, ME, Minty, E, Nyberg, F, Uribe, A, Recalde, M, Reich, C, Scheumie, M, Shah, K, Shah, N, Schilling, L, Vizcaya, D, Zhang, L, Hripcsak, G, Ryan, P, Prieto-Alhambra, D, Talita, D-S & Kostka, K 2023, 'Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe', Journal of Asthma, vol. 60, no. 1, pp. 76-86. https://doi.org/10.1080/02770903.2021.2025392

TY - JOUR

T1 - Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

AU - Morales, Daniel

AU - Ostropolets, Anna

AU - Lai, Lana

AU - Sena, Anthony

AU - DuVall, Scott

AU - Suchard, Marc

AU - Verhamme, Katia

AU - Rjinbeek, Peter

AU - Posada, Joe

AU - Ahmed, Waheed

AU - Alshammary, Thamer

AU - Alghoul, Heba

AU - Asler, Osaid

AU - Areia, Carlos

AU - Blacketer, Clair

AU - Burn, Ed

AU - Casajust, Paula

AU - You, Seng

AU - Dawoud, Dalia

AU - Golozar, Asieh

AU - Gong, Menchung

AU - Jonnagaddala, Jitendra

AU - Lynch, Kristine

AU - Matheny, Michael E.

AU - Minty, Evan

AU - Nyberg, Fredrik

AU - Uribe, Albert

AU - Recalde, Martina

AU - Reich, Christian

AU - Scheumie, Martijn

AU - Shah, Karishma

AU - Shah, Nigam

AU - Schilling, Lisa

AU - Vizcaya, David

AU - Zhang, Lin

AU - Hripcsak, George

AU - Ryan, Patrick

AU - Prieto-Alhambra, Daniel

AU - Talita, Duarte-Salles

AU - Kostka, Kristin

N1 - Funding Information: This study was supported by Wellcome Trust (Grant 214588/Z/18/Z), Bill & Melinda Gates Foundation (Investment ID INV-016201 and INV-019257), Innovative Medicines Initiative 2 Joint Undertaking (No 806968). Copyright: © 2022 the author(s). Published with license by Taylor & Francis Group, LLC.

PY - 2023

Y1 - 2023

N2 - Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma.Methods: We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients (‘diagnosed’ and ‘hospitalized’) based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions.Results: The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6–8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7–6.8) to 18.5% (95% CI 18.2–18.8) in the diagnosed cohort and 5.2% (95% CI 4.0–6.8) to 20.5% (95% CI 18.6–22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8–2.4) to 16.9% (95% CI 13.8–20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15–30% of hospitalized COVID-19 asthma patients.Conclusion: The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients. KEY MESSAGES Asthma prevalence in COVID-19 patients varied internationally (5.2–20.5%).The prevalence of asthma exacerbation at presentation with COVID-19 in diagnosed and hospitalized patients was low. Comorbidities were common in COVID-19 patients with asthma.

AB - Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma.Methods: We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients (‘diagnosed’ and ‘hospitalized’) based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions.Results: The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6–8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7–6.8) to 18.5% (95% CI 18.2–18.8) in the diagnosed cohort and 5.2% (95% CI 4.0–6.8) to 20.5% (95% CI 18.6–22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8–2.4) to 16.9% (95% CI 13.8–20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15–30% of hospitalized COVID-19 asthma patients.Conclusion: The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients. KEY MESSAGES Asthma prevalence in COVID-19 patients varied internationally (5.2–20.5%).The prevalence of asthma exacerbation at presentation with COVID-19 in diagnosed and hospitalized patients was low. Comorbidities were common in COVID-19 patients with asthma.

KW - asthma

KW - COVID-19

KW - comorbidity

KW - epidemiology

KW - Asthma

UR - http://www.scopus.com/inward/record.url?scp=85125203585&partnerID=8YFLogxK

U2 - 10.1080/02770903.2021.2025392

DO - 10.1080/02770903.2021.2025392

M3 - Article

C2 - 35012410

SN - 0277-0903

VL - 60

SP - 76

EP - 86

JO - Journal of Asthma

JF - Journal of Asthma

IS - 1

ER -

Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Approaches for Creating Clinical Evidence of Treatment Effects in Routine Populations Excluded from Trials (ACCEPT) (Clinical Research Career Development Fellowship)

Cite this

Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

Approaches for Creating Clinical Evidence of Treatment Effects in Routine Populations Excluded from Trials (ACCEPT) (Clinical Research Career Development Fellowship)

Cite this